Saturday, December 2, 2023
No Result
View All Result
  • বাংলা সংস্করণ
Shomporko
Advertisement
  • Home
  • News
    • Daily News
    • Feature
    • Sports
  • CANADA
    • Canada Daily
    • Community News
    • Canada Politics
    • Canada Economy
    • Canada Health
  • Global
  • Bangladesh
  • Interview
  • Article
    • Analytical
  • LITERATURE
    • Story
    • Poem
  • Opinion
    • Columnists
  • More
    • Food & Beverage
    • HISTORY
    • Kids Page
    • Travel
    • HOME DECOR
    • Video
    • Social Media
    • Festival
  • Home
  • News
    • Daily News
    • Feature
    • Sports
  • CANADA
    • Canada Daily
    • Community News
    • Canada Politics
    • Canada Economy
    • Canada Health
  • Global
  • Bangladesh
  • Interview
  • Article
    • Analytical
  • LITERATURE
    • Story
    • Poem
  • Opinion
    • Columnists
  • More
    • Food & Beverage
    • HISTORY
    • Kids Page
    • Travel
    • HOME DECOR
    • Video
    • Social Media
    • Festival
No Result
View All Result
Shomporko
No Result
View All Result
Home Canada Daily

A Canadian company helped make one of the most promising vaccine candidates

by Shomporko
November 19, 2020
in Canada Daily, Dailynews
0
A Canadian company helped make one of the most promising vaccine candidates
0
SHARES
45
VIEWS
Share on FacebookShare on Twitter

A Canadian biotech company played a key role in developing one of the world’s most promising vaccine candidates that could be days away from seeking emergency approval in the U.S.

Pfizer announced Wednesday that its vaccine, previously believed to be 90 percent effective, now appears to be 95 percent effective following more interim results. The company is preparing to formally ask the U.S. Food and Drug Administration to approve the emergency use of the vaccine in the coming days.

Vancouver-based biotech company Acuitas Therapeutics contributed to the vaccine candidate by providing an important delivery technology that carries a critical but fragile part of the vaccine into human cells.

Pfizer’s vaccine uses a new approach called messenger RNA technology, which acts as a set of instructions for human cells. Essentially, a vaccine using messenger RNA technology can give directions to cells to make new proteins to help fight off a virus.

The challenge with messenger RNA technology is that it is delicate and can be broken down by the body. So Acuitas Therapeutics developed lipid nanoparticles that act as vehicles for the vaccine to help it get where it needs to be, according to Acuitas Therapeutics CEO and president Thomas Madden.

Pfizer’s vaccine candidate, if approved, could be challenging to distribute because it needs to be stored at -75 C. Madden said this temperature condition was the most cautious approach vaccine developers could take, but further studies may identify a more convenient storage temperature.

“We don’t have the ability to do long stability studies to establish a shelf life for the vaccine at a more convenient temperature,” he said, emphasizing the importance of getting the vaccine approved quickly.

Pfizer’s update comes two days after Moderna announced that its vaccine candidate appears to be 94.5 percent effective, according to early but incomplete analysis.

The federal government has signed deals with multiple companies, including Pfizer and Moderna, for tens of millions of doses. The approach was meant to ensure that as many Canadians as possible have access to the first vaccine once it’s available.

Pfizer studied a group of 44,000 volunteers by giving some the vaccine candidate and other dummy shots. So far 170 volunteers have been infected, and only eight volunteers who received the vaccine contracted COVID-19. Of those, one suffered serious effects of the disease.

The company estimates that it could have 50 million doses ready by the end of 2020, which would provide the necessary two shots for 25 million people. Pfizer could make up to 1.3 billion doses in 2021, enough for roughly 8 percent of the world’s population.

Acuitas Therapeutics is a relatively small biotech company with 25 employees working out of a building at the University of British Columbia. Formed in 2009, the company specializes in creating delivery systems for nucleic acid therapeutics based on lipid nanoparticles.

Photo credit: Collected

News source: CTV News

Previous Post

Ontario will not meet emissions targets because the issue is not a government priority:' AG

Next Post

Sristy Human Rights Society donates geyser machine

Shomporko

Related Posts

NORAD says storm won’t slow Santa’s travels
Canada Daily

NORAD says storm won’t slow Santa’s travels

December 25, 2022
Catholics return to GTA churches for full-capacity Christmas masses
Canada Daily

Catholics return to GTA churches for full-capacity Christmas masses

December 25, 2022
List of GTA school cancellations during holiday winter storm
Canada Daily

List of GTA school cancellations during holiday winter storm

December 23, 2022
Toronto could still be digging out from major winter storm on Christmas Day, city officials warn
Canada Daily

Toronto could still be digging out from major winter storm on Christmas Day, city officials warn

December 23, 2022
Popular arena in the Junction to close unexpectedly for months due to emergency roof repairs
Canada Daily

Popular arena in the Junction to close unexpectedly for months due to emergency roof repairs

December 22, 2022
Woman, child seriously injured after being hit by vehicle in Cedarvale
Canada Daily

Woman, child seriously injured after being hit by vehicle in Cedarvale

December 22, 2022
Next Post
Sristy Human Rights Society donates geyser machine

Sristy Human Rights Society donates geyser machine

Logo

Disclaimer:

The editorial team is not responsible for the content of the writing.

Publisher and Editor
Sonia Hoque

General Manager

Rewrite-Man

Reporter

Graphics
Mozammel Sarkar

Address:

Shomporko Magazine

59 Byng ave
Scarborough,
Ontario
M1L3N8

Phone :647-686-5432

 

Email: 
shomporko.magazine@gmail.com
2537765 Ontario Ltd

© 2020 Shomporko – Magazine Develop by RMITtech

No Result
View All Result
  • Home
  • NEWS
    • Daily News
    • Feature
    • Global
    • Politics
    • Sports
  • CANADA
    • Canada Daily
    • Community News
    • Canada Politics
    • Canada Economy
    • Canada Immigration
    • Canada Education
    • Canada Health
    • Canada Opinion
  • GLOBAL
  • INTERVIEW
  • ARTICLE
    • Analytical
  • LITERATURE
    • Story
    • Poem
  • OPINION
    • Opinion
    • Columnists
    • Legal Advice
  • ARTS
    • Home Decor
    • Sports
  • LIVING
    • Health
    • Food
    • Travel
    • HISTORY
    • Kids Page
  • MORE
    • Video
    • Social Media
    • Festival
  • বাংলা সংস্করণ

© 2019 Shomporko - Magazine Develop by RMITtech.

Translate »